PremiumRatingsSummit Therapeutics: Promising Clinical Developments and Financial Stability Drive Buy Rating Summit Therapeutics: Buy Rating Amid Promising Clinical Trials and Market Opportunities Summit Therapeutics Reports Q1 2025 Progress and Financials PremiumThe FlySummit Therapeutics selloff Friday on data overdone, says H.C. Wainwright Summit Therapeutics Receives Buy Rating Amid Promising Ivonescimab Developments and Strategic Trials BMO says Keytruda ‘still reigns’ after ivonescimab survival data PremiumThe FlySummit Therapeutics says new ivonescimab data clinically meaningful Wells says Summit, Akeso data ‘not the bull case,’ but not ‘bear case either’ Akeso reports ivonescimab receives NMPA approval to treat NSCLC in China 
